

Lund September 7, 2012

FOCUS ON OPPORTUNITIES WITH BSI AT THE "BONE SCAN INDEX MEETING" IN MALMÖ

EXINI participated in a "Bone Scan Index meeting" held at Skåne University Hospital, Malmö, Sweden. Some 40 participants listened to two well renowned international speakers, who talked about the great opportunities available with Bone Scan Index (BSI).

NUMEMA (Nuclear Medicine in Malmö) arranged the "Bone Scan Index meeting", a scientific meeting organized by Professor Lars Edenbrandt, diagnostic center, SUS Malmö and Professor Anders Bjartell, Urology SUS, Malmö. Urologists as well as oncologists and nuclear medicine physicians were inspired by the lectures in CRC auditorium.

The audience had the opportunity to listen to Professor Steven Larson, Memorial Sloan-Kettering Cancer Center, New York, USA, giving a presentation concerning "Prostate Cancer Imaging." He was convinced that BSI will become an important imaging biomarker in this area:

"Today there are no good biomarkers available to predict anticipated survival and monitor the prostate cancer patients with advanced disease. Also, the pharmaceutical industry has expressed a great need for biomarkers in the development of new drugs," he said.

Professor Kenichi Nakajima, Kanazawa University, Kanazawa, Japan, gave a lecture on the topic "Bone scan and oncology imaging in Japan: a new viewpoint for the classic imaging." He shared the experience about the large existing interest for EXINI bone and BSI in Japan, where there are almost 700 programs installed, and said:

"Today, BSI is used mainly as an important biomarker to gain knowledge of prognosis and response to therapy in prostate cancer with bone metastases. But the BSI may also play an important role in other oncological diseases, such as breast cancer with bone metastases. This autumn a large BSI study, involving at least 300 patients at 30 hospitals all over Japan, will be started.

"This meeting was very important, and EXINI contributed to an open dialogue between urology/oncology and nuclear medicine physicians about the possibilities of BSI," said Magnus Aurell, CEO EXINI Diagnostics AB.

For more information, please contact:

Magnus Aurell, CEO

Phone: +46 46-286 54 25

E-mail: magnus.aurell@exini.com

About EXINI Diagnostics AB (publ)

EXINI Diagnostics AB (publ) offers advanced solutions for medical decision support to hospitals worldwide. The system is based on advanced image analysis by artificial intelligence and can make its own interpretation of radiology images and provide diagnostic suggestions. In this way the system is used as a decision support for the diagnosing doctor. EXINI is working with products for the diagnosis of some of the most frequent endemic diseases such as coronary heart disease, cancer, dementia and Parkinson's disease. The company was founded in 1999 by Professor Lars Edenbrandt. EXINI is listed on the stock market NASDAQ OMX First North and has about 400 shareholders. Principal owner is Bo Håkansson. Thenberg & Kinde Fondkommission AB acts as Certified Adviser.